Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Anastasia N Piniaeva"'
Autor:
Ilya V. Gordeychuk, Liubov I. Kozlovskaya, Aleksandra A. Siniugina, Nadezhda V. Yagovkina, Vladimir I. Kuzubov, Konstantin A. Zakharov, Viktor P. Volok, Maria S. Dodina, Larissa V. Gmyl, Natalya A. Korotina, Rostislav D. Theodorovich, Yulia I. Ulitina, Dmitry I. Vovk, Marina V. Alikova, Anna A. Kataeva, Anna V. Kalenskaya, Irina V. Solovjeva, Elena V. Tivanova, Larissa Y. Kondrasheva, Antonina A. Ploskireva, Vasiliy G. Akimkin, Ksenia A. Subbotina, Georgy M. Ignatyev, Anastasia K. Korduban, Elena Y. Shustova, Ekaterina O. Bayurova, Alla S. Zhitkevich, Daria V. Avdoshina, Anastasia N. Piniaeva, Anastasia A. Kovpak, Liliya P. Antonova, Yulia V. Rogova, Anna A. Shishova, Yury Y. Ivin, Svetlana E. Sotskova, Konstantin A. Chernov, Elena G. Ipatova, Ekaterina A. Korduban, Aydar A. Ishmukhametov
Publikováno v:
Viruses, Vol 15, Iss 9, p 1828 (2023)
We present the results of a randomized, double-blind, placebo-controlled, multi-center clinical trial phase I/II of the tolerability, safety, and immunogenicity of the inactivated whole virion concentrated purified coronavirus vaccine CoviVac in volu
Externí odkaz:
https://doaj.org/article/888b158eaf434d709bf07e578aead9e6
Autor:
Liubov I. Kozlovskaya, Anastasia N. Piniaeva, Georgy M. Ignatyev, Ilya V. Gordeychuk, Viktor P. Volok, Yulia V. Rogova, Anna A. Shishova, Anastasia A. Kovpak, Yury Yu. Ivin, Liliya P. Antonova, Kirill M. Mefyod, Lyubov S. Prokosheva, Anna S. Sibirkina, Yuliya Yu. Tarasova, Ekaterina O. Bayurova, Olga S. Gancharova, Victoria V. Illarionova, Grigory S. Glukhov, Olga S. Sokolova, Konstantin V. Shaitan, Anastasia M. Moysenovich, Stanislav A. Gulyaev, Tatiana V. Gulyaeva, Andrey V. Moroz, Larissa V. Gmyl, Elena G. Ipatova, Mikhail P. Kirpichnikov, Alexey M. Egorov, Aleksandra A. Siniugina, Aydar A. Ishmukhametov
Publikováno v:
Emerging Microbes and Infections, Vol 10, Iss 1, Pp 1790-1806 (2021)
The unprecedented in recent history global COVID-19 pandemic urged the implementation of all existing vaccine platforms to ensure the availability of the vaccines against COVID-19 to every country in the world. Despite the multitude of high-quality p
Externí odkaz:
https://doaj.org/article/25dd68ffe74e41b1a33bb195f5965272
Autor:
Nadezhda V. Yagovkina, Lev M. Zheleznov, Ksenia A. Subbotina, Andrey A. Tsaan, Liubov I. Kozlovskaya, Ilya V. Gordeychuk, Anastasia K. Korduban, Yury Y. Ivin, Anastasia A. Kovpak, Anastasia N. Piniaeva, Anna A. Shishova, Elena Y. Shustova, Yusuf K. Khapchaev, Galina G. Karganova, Alexandra A. Siniugina, Tatiana V. Pomaskina, Aleksandr A. Erovichenkov, Konstantin Chumakov, Aydar A. Ishmukhametov
Publikováno v:
Frontiers in Immunology, Vol 13 (2022)
BackgroundEffective response to emerging pandemic threats is complicated by the need to develop specific vaccines and other medical products. The availability of broadly specific countermeasures that could be deployed early in the pandemic could sign
Externí odkaz:
https://doaj.org/article/bbeca342ee3848b59babc5aa3a6847f5
Autor:
Anastasia A. Kovpak, Anastasia N. Piniaeva, Oleg A. Gerasimov, Irina O. Tcelykh, Mayya Y. Ermakova, Anna N. Zyrina, Dmitry V. Danilov, Yury Y. Ivin, Liubov I. Kozlovskaya, Aydar A. Ishmukhametov
Publikováno v:
Vaccines, Vol 10, Iss 6, p 949 (2022)
Various types of COVID-19 vaccines, including adenovirus, mRNA, and inactivated ones, have been developed and approved for clinical use worldwide. Inactivated vaccines are produced using a proven technology that is widely used for the production of v
Externí odkaz:
https://doaj.org/article/f8c8d0bebff3422ab3318ea190b369ee
Autor:
Anna N. Zyrina, Irina O. Tselykh, Anastasia S. Bogdan, Anastasia Kovpak, Yury Yu. Ivin, Vladislav E. Vasilenko, Anastasia N. Piniaeva, Аnna A. Shishova
Publikováno v:
Medical academic journal. 2:183-189
BACKGROUND: Despite the large-scale development of vaccines against coronavirus infection, there is still no complete information about the antigenic structure of the SARS-CoV-2 virus particles. This article describes a method of obtaining a pure con
Autor:
Dmitry V. Danilov, Olga A. Shmeleva, Alexander S. Lunin, Liubov I. Kozlovskaya, Anastasia N. Piniaeva, Anna A. Shishova
Publikováno v:
Medical academic journal. 2:163-169
BACKGROUND: SARS-CoV-2 vaccine immunogenicity is evaluated in neutralization test with live virus. It is performed in a biosafety level 3 zone because requires live virus stage. Therefore, control laboratories should be certified for this class of wo
Autor:
Aydar A Ishmukhametov, Aleksandra A Siniugina, Nadezhda V Yagovkina, Vladimir I Kuzubov, Konstantin A Zakharov, Viktor P Volok, Maria S Dodina, Larissa V Gmyl, Natalya A Korotina, Rostislav D Theodorovich, Yulia I Ulitina, Andrey A Tsaan, Tatiana V Pomaskina, Anna V Kalenskaya, Irina V Solovjeva, Elena V Tivanova, Larissa Y Kondrasheva, Antonina A Ploskireva, Vasiliy G Akimkin, Ksenia A Subbotina, Georgy M Ignatyev, Anastasia K Korduban, Elena Y Shustova, Ekaterina O Bayurova, Alla S Kondrashova, Darya V Avdoshina, Anastasia N Piniaeva, Anastasia A Kovpak, Liliya P Antonova, Yulia V Rogova, Anna A Shishova, Yury Y Ivin, Svetlana E Sotskova, Konstantin A Chernov, Elena G Ipatova, Ekaterina A Korduban, Liubov I Kozlovskaya, Ilya V Gordeychuk
We present the results of a randomized, double-blind, placebo-controlled, multi-center clinical trial of the tolerability, safety, and immunogenicity of the inactivated whole virion concentrated purified coronavirus vaccine CoviVac in adult volunteer
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::9fa7f5e2e5807fe5981592d7795102a1
https://doi.org/10.1101/2022.02.08.22270658
https://doi.org/10.1101/2022.02.08.22270658